Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 8 (2011), Issue 4 (April)

1. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
   Prostate, 71(8): 899-907. [Abstract] [Full-text]
2. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer.
   Prostate, 71(8): 892-8. [Abstract] [Full-text]
3. GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP).
   Prostate, 71(8): 881-91. [Abstract] [Full-text]
4. Effect of electroporation-mediated diphtheria toxin A expression on PSA positive human prostate xenograft tumors in SCID mice.
   Prostate, 71(8): 872-80. [Abstract] [Full-text]
5. Chromosome 8 markers of metastatic prostate cancer in African American men: gain of the MIR151 gene and loss of the NKX3-1 gene.
   Prostate, 71(8): 857-71. [Abstract] [Full-text]
6. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.
   Prostate, 71(8): 846-56. [Abstract] [Full-text]
7. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo.
   Prostate, 71(8): 835-45. [Abstract] [Full-text]
8. Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.
   Prostate, 71(8): 824-34. [Abstract] [Full-text]
9. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo.
   Prostate, 71(8): 813-23. [Abstract] [Full-text]
10. Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB.
    Prostate, 71(8): 801-12. [Abstract] [Full-text]
11. Contemporary management of metastatic castration-resistant prostate cancer.
    Curr Opin Urol, 21(3): 241-7. [Abstract] [Full-text]
12. The effect of different control point sampling sequences on convergence of VMAT inverse planning.
    Phys Med Biol, 56(8): 2569-83. [Abstract] [Full-text]
13. Fixed number of segments in unidirectional decompositions of fluence matrices for step-and-shoot IMRT.
    Phys Med Biol, 56(8): 2601-15. [Abstract] [Full-text]
14. Open versus robotic-assisted radical prostatectomy: which is better?
    Curr Opin Urol, 21(3): 200-5. [Abstract] [Full-text]
15. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence.
    Curr Opin Urol, 21(3): 237-40. [Abstract] [Full-text]
16. Robotic radical prostatectomy: a critical analysis of the impact on cancer control.
    Curr Opin Urol, 21(3): 179-84. [Abstract] [Full-text]
17. Intermittent hormonal therapy for prostate cancer.
    Curr Opin Urol, 21(3): 248-51. [Abstract] [Full-text]
18. Robotic-assisted laparoscopic prostatectomy: a critical analysis of its impact on urinary continence.
    Curr Opin Urol, 21(3): 185-94. [Abstract] [Full-text]
19. Temporal characterization and in vitro comparison of cell survival following the delivery of 3D-conformal, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT).
    Phys Med Biol, 56(8): 2445-57. [Abstract] [Full-text]
20. The role of PET/computed tomography scan in the management of prostate cancer.
    Curr Opin Urol, 21(3): 230-6. [Abstract] [Full-text]
21. Robotic radical prostatectomy: a critical analysis of surgical quality.
    Curr Opin Urol, 21(3): 195-9. [Abstract] [Full-text]
22. Contemporary management of patients with T1a and T1b prostate cancer.
    Curr Opin Urol, 21(3): 252-6. [Abstract] [Full-text]
23. Contemporary imaging analyses of pelvic lymph nodes in the prostate cancer patient.
    Curr Opin Urol, 21(3): 211-8. [Abstract] [Full-text]
24. A critical analysis of the long-term impact of brachytherapy for prostate cancer: a review of the recent literature.
    Curr Opin Urol, 21(3): 219-24. [Abstract] [Full-text]
25. Surgical anatomy of the prostate in the era of radical robotic prostatectomy.
    Curr Opin Urol, 21(3): 173-8. [Abstract] [Full-text]
26. Contemporary role of radiation therapy in the adjuvant or salvage setting following radical prostatectomy.
    Curr Opin Urol, 21(3): 206-10. [Abstract] [Full-text]
27. Contemporary role of prostate cancer gene 3 in the management of prostate cancer.
    Curr Opin Urol, 21(3): 225-9. [Abstract] [Full-text]
28. Adaptive seamless design for an efficacy trial of replication-competent adenovirus-mediated suicide gene therapy and radiation in newly-diagnosed prostate cancer (ReCAP Trial).
    Contemp Clin Trials, 32(3): 453-60. [Abstract] [Full-text]
29. Hyaluronan suppresses prostate tumor cell proliferation through diminished expression of N-cadherin and aberrant growth factor receptor signaling.
    Exp Cell Res, 317(8): 1214-25. [Abstract] [Full-text]
30. A novel synthetic protoapigenone analogue, WYC02-9, induces DNA damage and apoptosis in DU145 prostate cancer cells through generation of reactive oxygen species.
    Free Radic Biol Med, 50(9): 1151-62. [Abstract] [Full-text]
31. Evaluating an intervention to increase cancer knowledge in racially diverse communities in South Carolina.
    Patient Educ Couns, 83(2): 256-60. [Abstract] [Full-text]
32. Mediated decision support in prostate cancer screening: a randomized controlled trial of decision counseling.
    Patient Educ Couns, 83(2): 240-6. [Abstract] [Full-text]
33. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
    Eur J Pharmacol, 658(2): 98-107. [Abstract] [Full-text]
34. Lack of association of IL-10 gene polymorphisms with prostate cancer: evidence from 11,581 subjects.
    Eur J Cancer, 47(7): 1072-9. [Abstract] [Full-text]
35. Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer.
    Mol Med Report, 4(3): 419-24. [Abstract] [Full-text]
36. Patients' perspectives on fecal incontinence after brachytherapy for localized prostate cancer.
    Dis Colon Rectum, 54(5): 615-21. [Abstract] [Full-text]
37. Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling.
    Cancer Invest, 29(4): 318-24. [Abstract] [Full-text]
38. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil?
    Invest Radiol, 46(5): 301-6. [Abstract] [Full-text]
39. Relation between pain and skeletal metastasis in patients with prostate or breast cancer.
    Clin Physiol Funct Imaging, 31(3): 193-5. [Abstract] [Full-text]
40. Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results.
    Eur Radiol, 21(5): 1111-8. [Abstract] [Full-text]
41. Prostate cancer stem cells and their potential roles in metastasis.
    J Surg Oncol, 103(6): 558-62. [Abstract] [Full-text]
42. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
    J Pathol, 224(1): 90-100. [Abstract] [Full-text]
43. Overexpression of vimentin in canine prostatic carcinoma.
    J Comp Pathol, 144(4): 308-11. [Abstract] [Full-text]
44. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions.
    Int J Radiat Oncol Biol Phys, 80(1): 6-16. [Abstract] [Full-text]
45. Comprehensive gene expression microarray analysis of Ets-1 blockade in PC3 prostate cancer cells and correlations with prostate cancer tissues: Insights into genes involved in the metastatic cascade.
    Int J Mol Med, 27(6): 811-9. [Abstract] [Full-text]
46. Costunolide induces apoptosis through nuclear calcium2+ overload and DNA damage response in human prostate cancer.
    J Urol, 185(5): 1967-74. [Abstract] [Full-text]
47. Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy.
    J Urol, 185(5): 1686-90. [Abstract] [Full-text]
48. A single center prospective study: prediction of postoperative general quality of life, potency and continence after radical retropubic prostatectomy.
    J Urol, 185(5): 1681-5. [Abstract] [Full-text]
49. Does hormone therapy exacerbate the adverse effects of radiotherapy in men with prostate cancer? A quality of life study.
    J Urol, 185(5): 1674-80. [Abstract] [Full-text]
50. A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal vesicle invasion (pT3b) after radical prostatectomy.
    J Urol, 185(5): 1691-7. [Abstract] [Full-text]
51. Overuse of imaging for staging low risk prostate cancer.
    J Urol, 185(5): 1645-9. [Abstract] [Full-text]
52. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
    J Urol, 185(5): 1650-5. [Abstract] [Full-text]
53. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
    J Urol, 185(5): 1656-60. [Abstract] [Full-text]
54. Pelvic lymph node dissection is associated with symptomatic venous thromboembolism risk during laparoscopic radical prostatectomy.
    J Urol, 185(5): 1661-5. [Abstract] [Full-text]
55. Image-guided radiotherapy (IGRT) for prostate cancer comparing kV imaging of fiducial markers with cone beam computed tomography (CBCT).
    Int J Radiat Oncol Biol Phys, 80(1): 301-5. [Abstract] [Full-text]
56. Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients.
    J Cancer Res Clin Oncol, 137(5): 811-9. [Abstract] [Full-text]
57. Long-term follow-up and risk of cancer death after radiation for post-prostatectomy rising prostate-specific antigen.
    Int J Radiat Oncol Biol Phys, 80(1): 62-8. [Abstract] [Full-text]
58. Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate.
    Int J Radiat Oncol Biol Phys, 80(1): 76-84. [Abstract] [Full-text]
59. Dosimetric impact of interfraction catheter movement in high-dose rate prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 80(1): 85-90. [Abstract] [Full-text]
60. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
    Int J Radiat Oncol Biol Phys, 80(1): 55-61. [Abstract] [Full-text]
61. A new formula for prostate cancer lymph node risk.
    Int J Radiat Oncol Biol Phys, 80(1): 69-75. [Abstract] [Full-text]
62. Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery.
    Cochrane Database Syst Rev, 4: CD008306. [Abstract] [Full-text]
63. Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery.
    Cochrane Database Syst Rev, 4: CD008306. [Abstract] [Full-text]
64. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    Int J Clin Pract, 65(5): 559-66. [Abstract] [Full-text]
65. Novel agents and new therapeutics in castration-resistant prostate cancer.
    Curr Opin Oncol, 23(3): 290-6. [Abstract] [Full-text]
66. Clinical importance of lymph node density in predicting outcome of prostate cancer patients.
    J Surg Res, 167(2): 267-72. [Abstract] [Full-text]
67. Impact of annual surgical volume on length of stay in patients undergoing minimally invasive prostatectomy: a population-based study.
    Eur J Surg Oncol, 37(5): 429-34. [Abstract] [Full-text]
68. Can molecular markers stratify the diagnostic value of high-grade prostatic intraepithelial neoplasia?
    Hum Pathol, 42(5): 702-9. [Abstract] [Full-text]
69. Positive visualization of implanted devices with susceptibility gradient mapping using the original resolution.
    Magn Reson Med, 65(5): 1483-90. [Abstract] [Full-text]
70. Cellular and molecular effects of the liposomal mTHPC derivative Foslipos in prostate carcinoma cells in vitro.
    Photodiagnosis Photodyn Ther, 8(2): 86-96. [Abstract] [Full-text]
71. Comparison of quantum-dots- and fluorescein-isothiocyanate-based technology for detecting prostate-specific antigen expression in human prostate cancer.
    IET Nanobiotechnol, 5(2): 47. [Abstract] [Full-text]
72. Accelerated T2 mapping for characterization of prostate cancer.
    Magn Reson Med, 65(5): 1400-6. [Abstract] [Full-text]
73. Frequency-domain analysis of photoacoustic imaging data from prostate adenocarcinoma tumors in a murine model.
    Ultrasound Med Biol, 37(5): 834-9. [Abstract] [Full-text]
74. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells.
    Biochim Biophys Acta, 1813(5): 683-94. [Abstract] [Full-text]
75. External validation of a model to predict the survival of patients presenting with a spinal epidural metastasis.
    Cancer Metastasis Rev, 30(2): 153-9. [Abstract] [Full-text]
76. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFκB pathway in the Noble rat model.
    J Nutr Biochem, 22(5): 502-10. [Abstract] [Full-text]
77. Loss of cell surface TFII-I promotes apoptosis in prostate cancer cells stimulated with activated α₂ -macroglobulin.
    J Cell Biochem, 112(6): 1685-95. [Abstract] [Full-text]
78. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer.
    Radiology, 259(2): 453-61. [Abstract] [Full-text]
79. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells.
    Int J Oncol, 38(6): 1759-66. [Abstract] [Full-text]
80. Suppression of growth and invasive behavior of human prostate cancer cells by ProstaCaid™: mechanism of activity.
    Int J Oncol, 38(6): 1675-82. [Abstract] [Full-text]
81. Vav3 oncogene is involved in regulation of secretory phospholipase A2-IIa expression in prostate cancer.
    Oncol Rep, 25(6): 1511-6. [Abstract] [Full-text]
82. Pancratistatin induces apoptosis and autophagy in metastatic prostate cancer cells.
    Int J Oncol, 38(6): 1549-56. [Abstract] [Full-text]
83. Prostate cancer ablation with transrectal high-intensity focused ultrasound: assessment of tissue destruction with contrast-enhanced US.
    Radiology, 259(2): 583-91. [Abstract] [Full-text]
84. Expression profile of WNT molecules in prostate cancer and its regulation by aminobisphosphonates.
    J Cell Biochem, 112(6): 1593-600. [Abstract] [Full-text]
85. A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance.
    J Clin Epidemiol, 64(6): 628-36. [Abstract] [Full-text]
86. Calmodulin protects androgen receptor from calpain-mediated breakdown in prostate cancer cells.
    J Cell Physiol, 226(7): 1889-96. [Abstract] [Full-text]
87. Differential transformation capacity of Src family kinases during the initiation of prostate cancer.
    Proc Natl Acad Sci U S A, 108(16): 6579-84. [Abstract] [Full-text]
88. Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process.
    Proc Natl Acad Sci U S A, 108(16): 6591-6. [Abstract] [Full-text]
89. Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
    J Clin Oncol, 29(12): 1517-24. [Abstract] [Full-text]
90. Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer.
    Nucl Med Commun, 32(6): 475-8. [Abstract] [Full-text]
91. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
    Cancer Immunol Immunother, 60(5): 715-30. [Abstract] [Full-text]
92. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
    J Magn Reson Imaging, 33(5): 1160-70. [Abstract] [Full-text]
93. Endorectal MRI after radiation therapy: questioning the sextant analysis.
    J Magn Reson Imaging, 33(5): 1086-90. [Abstract] [Full-text]
94. Do polymorphisms in XRCC4 influence prostate cancer susceptibility in North Indian population?
    Biomarkers, 16(3): 236-42. [Abstract] [Full-text]
95. Human papillomavirus 16 or 18 infection and prostate cancer risk: a meta-analysis.
    Ir J Med Sci, 180(2): 497-503. [Abstract] [Full-text]
96. A rapid access diagnostic clinic for prostate cancer: the experience after one year.
    Ir J Med Sci, 180(2): 505-8. [Abstract] [Full-text]
97. Wnt/β-catenin activation promotes prostate tumor progression in a mouse model.
    Oncogene, 30(16): 1868-79. [Abstract] [Full-text]
98. Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
    Clin Exp Metastasis, 28(5): 479-91. [Abstract] [Full-text]
99. Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer.
    Am J Pathol, 178(5): 2367-76. [Abstract] [Full-text]
100. A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis.
     Chem Biol, 18(4): 476-84. [Abstract] [Full-text]
101. T1 hyperintensity of bladder urine at prostate MRI: frequency and comparison with urinalysis findings.
     Clin Imaging, 35(3): 203-7. [Abstract] [Full-text]
102. Identification of an interaction between the TPalpha and TPbeta isoforms of the human thromboxane A2 receptor with protein kinase C-related kinase (PRK) 1: implications for prostate cancer.
     J Biol Chem, 286(17): 15440-57. [Abstract] [Full-text]
103. γ-Tocotrienol induces growth arrest through a novel pathway with TGFβ2 in prostate cancer.
     Free Radic Biol Med, 50(10): 1344-54. [Abstract] [Full-text]
104. Meta-analysis of three polymorphisms in the steroid-5-alpha-reductase, alpha polypeptide 2 gene (SRD5A2) and risk of prostate cancer.
     Mutagenesis, 26(3): 371-83. [Abstract] [Full-text]
105. Effect of testosterone administration to men with prostate cancer is unpredictable: a word of caution and suggestions for a registry.
     BJU Int, 107(9): 1369-73. [Abstract] [Full-text]
106. Prostate cancer and diet: food for thought?
     BJU Int, 107(9): 1348-59. [Abstract] [Full-text]
107. Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer.
     Int J Urol, 18(5): 358-62. [Abstract] [Full-text]
108. Use of Chinese medicine among prostate cancer patients in Taiwan: a retrospective longitudinal cohort study.
     Int J Urol, 18(5): 383-6. [Abstract] [Full-text]
109. Antibiotics and observation have a similar impact on asymptomatic patients with a raised PSA.
     BJU Int, 107(10): 1576-81. [Abstract] [Full-text]
110. Focal therapy in the management of localized prostate cancer.
     BJU Int, 107(9): 1362-8. [Abstract] [Full-text]
111. LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer.
     Int J Cancer, 128(12): 2843-52. [Abstract] [Full-text]
112. Decision-making in localized prostate cancer: lessons learned from an online support group.
     BJU Int, 107(10): 1570-5. [Abstract] [Full-text]
113. Pathological characterization of unifocal prostate cancers in whole-mount radical prostatectomy specimens.
     BJU Int, 107(10): 1587-91. [Abstract] [Full-text]
114. Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer.
     BJU Int, 107(9): 1400-3. [Abstract] [Full-text]
115. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging.
     BJU Int, 107(9): 1411-8. [Abstract] [Full-text]
116. Contrast-enhanced ultrasonography of the prostate: various imaging findings that indicate prostate cancer.
     BJU Int, 107(9): 1404-10. [Abstract] [Full-text]
117. Cumulative summation graphs are a useful tool for monitoring positive surgical margin rates in robot-assisted radical prostatectomy.
     BJU Int, 107(10): 1648-52. [Abstract] [Full-text]
118. Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.
     BJU Int, 107(10): 1562-9. [Abstract] [Full-text]
119. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?
     BJU Int, 107(10): 1582-6. [Abstract] [Full-text]
120. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.
     BJU Int, 107(9): 1488-99. [Abstract] [Full-text]
121. Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer.
     BJU Int, 107(9): 1419-24. [Abstract] [Full-text]
122. Role of p115RhoGEF in the regulation of extracellular Ca(2+)-induced choline kinase activation and prostate cancer cell proliferation.
     Int J Cancer, 128(12): 2833-42. [Abstract] [Full-text]
123. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.
     Cancer, 117(10): 2086-95. [Abstract] [Full-text]
124. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
     Cancer, 117(10): 2077-85. [Abstract] [Full-text]
125. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
     Cancer, 117(10): 2058-66. [Abstract] [Full-text]
126. Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape.
     Proc Natl Acad Sci U S A, 108(17): 6853-6. [Abstract] [Full-text]
127. The vanilloid capsaicin induces IL-6 secretion in prostate PC-3 cancer cells.
     Cytokine, 54(3): 330-7. [Abstract] [Full-text]
128. The significance of Her2 on androgen receptor protein stability in the transition of androgen requirement in prostate cancer cells.
     Am J Physiol Endocrinol Metab, 300(5): E902-8. [Abstract] [Full-text]
129. Patients' desire to preserve sexual activity and final decision for a nerve-sparing approach: results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study.
     J Sex Med, 8(5): 1495-502. [Abstract] [Full-text]
130. Cutaneous metastasis of prostatic adenocarcinoma: a cautionary tale.
     J Cutan Pathol, 38(6): 521-4. [Abstract] [Full-text]
131. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis.
     Eur Urol, 59(5): 832-40. [Abstract] [Full-text]
132. Safety profile of robot-assisted radical prostatectomy: a standardized report of complications in 3317 patients.
     Eur Urol, 59(5): 684-98. [Abstract] [Full-text]
133. MicroRNA in prostate, bladder, and kidney cancer: a systematic review.
     Eur Urol, 59(5): 671-81. [Abstract] [Full-text]
134. Pentafecta: a new concept for reporting outcomes of robot-assisted laparoscopic radical prostatectomy.
     Eur Urol, 59(5): 702-7. [Abstract] [Full-text]
135. Exosomes as biomarker treasure chests for prostate cancer.
     Eur Urol, 59(5): 823-31. [Abstract] [Full-text]
136. Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function.
     Brachytherapy, 10(3): 195-200. [Abstract] [Full-text]
137. A simple method for dose fusion from multimodality treatment of prostate cancer: brachytherapy to external beam therapy.
     Brachytherapy, 10(3): 214-20. [Abstract] [Full-text]
138. Precedence for prostate brachytherapy.
     Brachytherapy, 10(3): 201-7. [Abstract] [Full-text]
139. Effects of ellipsoid prostate deformation on dose delivery during permanent interstitial brachytherapy.
     Brachytherapy, 10(3): 208-13. [Abstract] [Full-text]
140. Purification and direct transformation of epithelial progenitor cells from primary human prostate.
     Nat Protoc, 6(5): 656-67. [Abstract] [Full-text]
141. Molecular diagnostics in urologic malignancies: a work in progress.
     Arch Pathol Lab Med, 135(5): 610-21. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.